Ocuphire Pharma Investor Day Presentation Deck slide image

Ocuphire Pharma Investor Day Presentation Deck

RM 55 MIRA-2: Mean Pupil Diameter Over Time by Mydriatic Agent Nyxol Reduced Pupil Diameter with All Mydriatic Agents; More Rapidly with Phenylephrine as Expected Pupil Diameter (mm) 9 8 4Mydriatic 3 Max pupil dilation, Treatment -1 Phenylephrine (Study Eye) Mean Pupil Diameter p<0.0001 p<0.0001 0 0.5 1 p<0.0001 MIRA-2 Phase 3 Trial Nyxol Reduced PD Faster Across All Mydriatic Agents F4 KA p<0.0001 p<0.0001 K Nyxol n=56 Placebo n=55 p<0.0001 2 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) 6 Source: MIRA-2 TLR table #14.2.2.3 (mITT). Standard Error bars are shown. p<0.0001 24 Pupil Diameter (mm) 9 8 3 Mydriatic -1 Tropicamide or Paremyd (Study Eye) Mean Pupil Diameter p<0.0001 Max pupil dilation, Treatment p<0.0001 0 0.5 1 p<0.0001 H p<0.0001 F 1 p<0.0001 -Nyxol n=38 Placebo n=36 HA p<0.0001 5 2 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) 6 7 p<0.0001 24 Ocuphire PHARMA
View entire presentation